Intranasal Neuropeptide Y is Most Effective in Some Aspects of Acute Stress Compared to Melatonin, Oxytocin and Orexin

Overview

Journal Front Pharmacol

Date 2022 Dec 19

PMID 36532718

Authors

Eugene Zubkov

Olga Abramova

Yana Zorkina

Aleksandra Ochneva

Valeria Ushakova

Anna Morozova

Olga Gurina

Alexander Majouga

Vladimir Chekhonin

Affiliations

Soon will be listed here.

Abstract

In the current study, we compared the effects of a single intranasal administration of clomipramine with effects of four neuropeptides, melatonin, oxytocin, orexin, and neuropeptide Y, to compare them in an acute stress model. The anti-stress effect was evaluated in the sucrose preference and forced swimming tests. Serum corticosterone level in rats was measured to evaluate the stress response. Neuropeptide Y reduced immobilization time in the Porsolt test and decreased corticosterone levels, but increased the anhedonia. Orexin had no positive effect on animal behavior, but decreased corticosterone levels. Oxytocin decreased immobilization time, maintained anhedonia at the level of control, but did not affect corticosterone levels. Melatonin demonstrated no positive effects in any of the tests. The intranasal administered neuropeptide Y could be a promising compound for the treatment of stress disorders.

Citing Articles

The Role of Neuropeptide Y in the Pathogenesis of Alzheimer's Disease: Diagnostic Significance and Neuroprotective Functions.

Shapovalova K, Zorkina Y, Abramova O, Andryushchenko A, Chekhonin V, Kostyuk G Neurol Int. 2024; 16(6):1318-1331.

PMID: 39585059 PMC: 11587103. DOI: 10.3390/neurolint16060100.

References

Nahvi R, Tanelian A, Nwokafor C, Hollander C, Peacock L, Sabban E . Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females. Front Behav Neurosci. 2021; 15:705579. PMC: 8456029. DOI: 10.3389/fnbeh.2021.705579. View

Witkin J, Martin A, Golani L, Xu N, Smith J . Rapid-acting antidepressants. Adv Pharmacol. 2019; 86:47-96. DOI: 10.1016/bs.apha.2019.03.002. View

Morilak D, Barrera G, Echevarria D, Garcia A, Hernandez A, Ma S . Role of brain norepinephrine in the behavioral response to stress. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(8):1214-24. DOI: 10.1016/j.pnpbp.2005.08.007. View

Serova L, Laukova M, Alaluf L, Pucillo L, Sabban E . Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model. Eur Neuropsychopharmacol. 2013; 24(1):142-7. DOI: 10.1016/j.euroneuro.2013.11.007. View

Liu M, Yin C, Zhu L, Zhu X, Xu C, Luo C . Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc. 2018; 13(7):1686-1698. DOI: 10.1038/s41596-018-0011-z. View

Orsetti M, Canonico P, Dellarole A, Colella L, di Brisco F, Ghi P . Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology. 2007; 32(8):1783-90. DOI: 10.1038/sj.npp.1301291. View

Abramova O, Zorkina Y, Ushakova V, Zubkov E, Morozova A, Chekhonin V . The role of oxytocin and vasopressin dysfunction in cognitive impairment and mental disorders. Neuropeptides. 2020; 83:102079. DOI: 10.1016/j.npep.2020.102079. View

Schneiderman N, Ironson G, Siegel S . Stress and health: psychological, behavioral, and biological determinants. Annu Rev Clin Psychol. 2007; 1:607-28. PMC: 2568977. DOI: 10.1146/annurev.clinpsy.1.102803.144141. View

Musazzi L, Milanese M, Farisello P, Zappettini S, Tardito D, Barbiero V . Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One. 2010; 5(1):e8566. PMC: 2797327. DOI: 10.1371/journal.pone.0008566. View

10.

Abramova O, Zorkina Y, Syunyakov T, Zubkov E, Ushakova V, Silantyev A . Brain Metabolic Profile after Intranasal vs. Intraperitoneal Clomipramine Treatment in Rats with Ultrasound Model of Depression. Int J Mol Sci. 2021; 22(17). PMC: 8431753. DOI: 10.3390/ijms22179598. View

11.

Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger Jr J, Lisanby S . A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med. 2020; 26(5):760-768. PMC: 9949770. DOI: 10.1038/s41591-020-0806-7. View

12.

Boaden K, Tomlinson A, Cortese S, Cipriani A . Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment. Front Psychiatry. 2020; 11:717. PMC: 7493620. DOI: 10.3389/fpsyt.2020.00717. View

13.

Balk R, Bridi J, de Lima Portella R, Carvalho N, Dobrachinski F, da Silva M . Clomipramine treatment and repeated restraint stress alter parameters of oxidative stress in brain regions of male rats. Neurochem Res. 2010; 35(11):1761-70. DOI: 10.1007/s11064-010-0240-1. View

14.

Tonon A, Pilz L, Markus R, Hidalgo M, Elisabetsky E . Melatonin and Depression: A Translational Perspective From Animal Models to Clinical Studies. Front Psychiatry. 2021; 12:638981. PMC: 8060443. DOI: 10.3389/fpsyt.2021.638981. View

15.

Garcia-Keller C, Carter J, Kruyer A, Kearns A, Hopkins J, Hodebourg R . Behavioral and accumbens synaptic plasticity induced by cues associated with restraint stress. Neuropsychopharmacology. 2021; 46(10):1848-1856. PMC: 8357931. DOI: 10.1038/s41386-021-01074-7. View

16.

Suvrathan A, Tomar A, Chattarji S . Effects of chronic and acute stress on rat behaviour in the forced-swim test. Stress. 2010; 13(6):533-40. DOI: 10.3109/10253890.2010.489978. View

17.

Valdes-Tovar M, Estrada-Reyes R, Solis-Chagoyan H, Argueta J, Dorantes-Barron A, Quero-Chavez D . Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression. Br J Pharmacol. 2018; 175(16):3200-3208. PMC: 6057892. DOI: 10.1111/bph.14197. View

18.

Liao Y, Xing Q, Li Q, Zhang J, Pan R, Yuan Z . Astrocytes in depression and Alzheimer's disease. Front Med. 2021; 15(6):829-841. DOI: 10.1007/s11684-021-0875-0. View

19.

Bansal Y, Kuhad A . Mitochondrial Dysfunction in Depression. Curr Neuropharmacol. 2016; 14(6):610-8. PMC: 4981740. DOI: 10.2174/1570159x14666160229114755. View

20.

Ji M, Zhang X, Chen Z, Wang J, Zhu J . Orexin prevents depressive-like behavior by promoting stress resilience. Mol Psychiatry. 2018; 24(2):282-293. PMC: 6755988. DOI: 10.1038/s41380-018-0127-0. View